Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025

Rhea-AI Summary

Amicus Therapeutics (FOLD) has scheduled a conference call and live audio webcast for February 19, 2025, at 8:30 a.m. ET to discuss their full-year 2024 financial results. Participants must pre-register online to receive dial-in details and a personal PIN for phone access. A webcast will be available through the Investors section of Amicus' website, with participants advised to register 15 minutes before the call starts.

The presentation materials and archived webcast will be accessible on the company's website after the event. Amicus Therapeutics is a global biotechnology company focused on developing and delivering medicines for rare diseases.

News Market Reaction

-0.10%

1 alert

-0.10% News Effect

On the day this news was published, FOLD declined 0.10%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 19, 2025, at 8:30 a.m. ET to discuss financial results for the full-year ended December 31, 2024.

Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com. Web participants are encouraged to register on the website 15 minutes prior to the start of the call.

An archived webcast and accompanying slides will be available on the Company's website shortly after the conclusion of the live event.

About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on X and LinkedIn.

CONTACT:

Investors:
Amicus Therapeutics
Andrew Faughnan
Vice President, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809

Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Affairs and Communications
dmoore@amicusrx.com
(609) 662-5079

FOLD–G

FAQ

When will Amicus Therapeutics (FOLD) release its full-year 2024 financial results?

Amicus Therapeutics will release its full-year 2024 financial results on February 19, 2025, during a conference call and webcast at 8:30 a.m. ET.

How can investors access FOLD's full-year 2024 earnings call?

Investors can access the call either by phone through online registration to receive dial-in details and PIN, or via live audio webcast through the Investors section at ir.amicusrx.com.

Will FOLD's earnings presentation materials be available after the call?

Yes, the archived webcast and accompanying presentation slides will be available on Amicus Therapeutics' website shortly after the live event concludes.

What time should investors register for FOLD's earnings webcast?

Web participants are encouraged to register on the website 15 minutes prior to the start of the call, which begins at 8:30 a.m. ET.